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Mandating HPV Vaccination — Private Rights, Public Good
To the Editor: Those who oppose mandating 
vaccination against human papillomavirus (HPV) 
as a condition for school entry generally open the 
debate with two fundamental questions. First, 
how can the government interfere in the medical 
decisions parents make for their children by 
compelling immunizations for school entry? Sec-
ond, how can the HPV vaccine be a good candi-
date for school mandates when HPV infection is 
transmitted only through intimate contact, not 
through casual encounters, as with other diseas-
es that are preventable with vaccines? In fact, re-
quiring vaccination against HPV for school entry 
is firmly rooted in American jurisprudence.
The Supreme Court, when first adjudicating 
compelled vaccination, recognized that the “po-
lice power” granted to states under the Consti-
tution’s 10th Amendment permits all jurisdictions 
to legislate to “protect the public health and the 
public safety.”1 Thus, the Court said, Massachu-
setts was acting within its appropriate authority 
when requiring persons to submit to vaccination 
against smallpox and when imposing sanctions 
for noncompliance. Seventeen years later, the 
Court affirmed a Texas mandate that required 
documentation of the receipt of certain vaccina-
tions before children could enter school.2
Today, all states and the District of Columbia 
have instituted immunization requirements for 
school entry and all jurisdictions provide a pro-
cedure for parents to opt out of the requirements. 
These mandates have proved to be the most ef-
fective tool ever devised for increasing access to 
recommended vaccines for our children. Indeed, 
the national coverage rate for most childhood vac-
cines is 95%.3
Another argument against compulsory HPV 
vaccination contends that because the infection 
is not casually communicable, the traditional justi-
fications outlined in previous judicial decisions do 
not apply. However, the mode of transmission is 
a distinction without meaningful difference, and 
the result is the same. Twenty million persons 
are currently infected with HPV; 6 million more 
become infected each year. The threat to the 
public’s health, at least with respect to vaccine-
related strains, is preventable with the vaccine.
Legal precedent, although established before 
the introduction of the new vaccine against a vi-
rus that is transmitted through intimate contact, 
will nevertheless serve as the nexus for decisions 
about the future. If courts are ever called on to 
review the appropriateness of mandating vacci-
nation against HPV, the traditional underlying 
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principles set forth to justify vaccine mandates 
could easily outweigh concerns about the mode 
of transmission. Courts must rely on and respect 
the established precedent on which immuniza-
tion mandates have been built.
Alexandra M. Stewart, J.D.
George Washington University Medical Center 
Washington, DC 20006  
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Treatment of Infertility in the Polycystic Ovary Syndrome
To the Editor: In their report on the treatment 
of infertility in women with the polycystic ovary 
syndrome, Legro et al. (Feb. 8 issue)1 do not men-
tion lifestyle interventions, although a significant 
proportion of the women in their study were 
obese. Many studies have shown that weight re-
duction normalizes ovulation, improves hyper-
androgenism, and ultimately increases rates of 
conception among women with the polycystic 
ovary syndrome.2 In fact, ovulation rates similar 
to those achieved in the two recent trials with 
metformin1,3 have been previously reported in 
association with lifestyle interventions.4
In addition to infertility in anovulatory women, 
the polycystic ovary syndrome is associated with 
metabolic disorders that are linked to insulin re-
sistance and central obesity.5 The administration 
of clomiphene alone does not target these abnor-
malities, and in the study by Legro et al. it actu-
ally led to increases in weight and insulin resis-
tance. In contrast, weight loss has been associated 
with a significant reduction of visceral fat, lead-
ing to an improved metabolic profile.2
On the basis of this evidence, we believe that 
lifestyle modifications — increased exercise, a 
properly supervised diet, and smoking cessation 
— should be the first and are probably the most 
important steps in the therapeutic approach to 
the polycystic ovary syndrome in obese women.
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To the Editor: Legro et al. assert that the infe-
riority of metformin in achieving live births is in-
consistent with the findings of previous studies, 
which show the benefits of metformin in stimu-
lating ovulation. However, in the previous stud-
ies, subjects received metformin in an immediate-
release form, whereas the subjects in the study by 
Legro et al. received metformin in the extended-
release form, which may not be as efficacious in 
lowering insulin, androgen, and sex hormone–
binding globulin levels.
Clinical experience with extended-release met-
formin suggests that it is not as effective as the 
immediate-release form for glycemic control. The 
nonsignificant decreases in the levels of glucose, 
insulin, proinsulin, and insulin resistance as de-
termined by homeostasis model assessment as-
sociated with metformin in the study by Legro 
and colleagues provide support for this impres-
sion. In an initial study of immediate-release 
metformin, reported by Nestler and Jakubowicz,1 
sex hormone–binding globulin levels increased 
by 187.5% (vs. a 12.0% increase with extended-
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